|
|
|
|
Long-awaited drug fights renal cancer
For the first time in more than 10 years, the Food & Drug Administration has granted marketing approval to a drug for kidney cancer. Sorafenib was recently approved for the treatment of advanced renal cell carcinoma, the most common form of the disease. Sorafenib is currently available through specialty pharmacies.
|
| |
More>>
|
|
|
|
|
|
Optimizing management of HF
A 60-year-old African-American male, G.H., is admitted to your hospital with shortness of breath, peripheral edema, and 10-lb. weight gain, diagnosed as New York Heart Association Class III heart failure (HF).
|
| |
More>>
|
|
|
|
|
|
Muraglitazar: A dual peroxisome proliferator-activated receptor agonist
Muraglitazar is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. Available clinical data describe improvements in glycemic parameters similar to available thiazolidinediones. Safety data are limited, but in available abstracts, there are reports of moderately elevated rates of edema, weight gain, and hypoglycemia with muraglitazar compared with placebo or pioglitazone.
|
| |
More>>
|
|
|
|
|
|
Once-daily tablet treats iron overload
The Food & Drug Administration has approved deferasirox for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in adults and children age two and older. "Iron overload is a potentially fatal consequence among patients with sickle cell disease, myelodysplastic syndromes, and thalassemia who regularly receive blood transfusions," said Alice Cohen, M.D., director of the division of hematology and oncology at Newark Beth Israel Medical Center, Newark, N.J.
|
| |
More>>
|
|
|
